OZEM

Roundhill GLP-1 & Weight Loss ETF

$32.01

+0.00%

Market closed. Last update: 11:58 AM ET

📎 Investment Objective

The Roundhill GLP-1 & Weight Loss ETF seeks to provide investment results that, before fees and expenses, correspond generally to the performance of the Roundhill GLP-1 & Weight Loss Index.

Overview

ETF tracking Roundhill GLP-1 & Weight Loss ETF

Category Emerging Markets

Issuer Other

Inception Date 2024-05-21

Market Cap $40.3M

Average Volume N/A

Dividend Yield 0.17%

52-Week Range $20.67 - $31.90

VWAP $31.96

Performance

Loading performance data...

Price Chart

Investment Summary

📎 Investment Objective

The Roundhill GLP-1 & Weight Loss ETF seeks to provide investment results that, before fees and expenses, correspond generally to the performance of the Roundhill GLP-1 & Weight Loss Index.

🎯 Investment Strategy

The ETF invests in a portfolio of companies that are involved in the development, manufacturing, and distribution of glucagon-like peptide-1 (GLP-1) agonists and other weight loss therapies. The fund aims to track the performance of the underlying index, which is designed to measure the stock performance of such companies.

✨ Key Features

Focuses on the emerging GLP-1 and weight loss therapy industry
Provides exposure to companies at the forefront of innovative weight management solutions
Seeks to track the performance of the Roundhill GLP-1 & Weight Loss Index
Relatively new fund with limited performance history

⚠️ Primary Risks

Emerging market risk: The fund invests in companies in the emerging GLP-1 and weight loss therapy industry, which may be subject to higher volatility and less liquidity than more established markets
Concentration risk: The fund's investments are concentrated in the GLP-1 and weight loss therapy industry, which may be more volatile than a more diversified portfolio
Regulatory risk: Changes in government regulations or policies related to GLP-1 agonists and weight loss therapies could adversely impact the fund's performance
Limited performance history: As a new fund, it has a limited track record, making it difficult to evaluate its long-term performance and suitability

👤 Best For

This ETF may be suitable for investors with a higher risk tolerance who are seeking exposure to the emerging GLP-1 and weight loss therapy industry. It may be appropriate as a satellite holding in a diversified portfolio, rather than as a core investment. Investors should be aware of the fund's concentration risk and limited performance history.